Skip to main content
SpringerLink
Log in

Surgical Management and Emerging Therapies to Prolong Survival in Metastatic Neuroendocrine Cancer

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010 Jun 29 [Epub ahead of print].

  2. Elias D, Lefevre JH, Duvillard P, et al. Hepatic metastases from neuroendocrine tumors with a “thin slice” pathological examination: they are many more than you think. Ann Surg. 2010;251:307–10.

    Article  PubMed  Google Scholar 

  3. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17:1733–42.

    Article  PubMed  CAS  Google Scholar 

  4. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–63.

    Article  PubMed  CAS  Google Scholar 

  5. Alsamarai S, Libutti SK, Saif MW. Updates in pancreatic neuroendocrine carcinoma. Highlights from the “2010 ASCO Annual Meeting.” Chicago, IL. June 4–8, 2010. JOP. 2010;11:336–40.

  6. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.

    Article  PubMed  CAS  Google Scholar 

  7. Saxena A, Chua TC, Bester L, Kokandi A, Morris DL. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg. 2010;251:910–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery and Division of Surgical Oncology, Hepatobiliary Surgery Program, The Johns Hopkins Hospital, 600, N Wolfe St., Harvey 611, Baltimore, MD, USA

    Skye C. Mayo MD, MPH, Mechteld C. de Jong MD & Timothy M. Pawlik MD, MPH, FACS

Authors
  1. Skye C. Mayo MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mechteld C. de Jong MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timothy M. Pawlik MD, MPH, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy M. Pawlik MD, MPH, FACS.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mayo, S.C., de Jong, M.C. & Pawlik, T.M. Surgical Management and Emerging Therapies to Prolong Survival in Metastatic Neuroendocrine Cancer. Ann Surg Oncol 18 (Suppl 3), 220–221 (2011). https://doi.org/10.1245/s10434-010-1343-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-010-1343-2

Keywords

Search

Navigation